Butardo, et al, COVID and Brain Fog

1	Clearing the Fog: A Systematic Review on Cognitive Dysfunction in COVID-19
2	Nicole D. Butardo <sup>1</sup> , Mikaela Frances D. Coronel <sup>1</sup> , Alanna Marie O. Dino <sup>1</sup> , Tiffany Ritz
3	F. Mendoza <sup>1</sup> , Oliver Kyle DC. Sto. Domingo <sup>1</sup> , Zypher Jude G. Regencia <sup>2,3</sup> ,
4	Jacqueline C. Dominguez <sup>4</sup> , Emmanuel S. Baja <sup>2,3</sup> , and Antonio D. Ligsay <sup>1,5,6,*</sup>
5	
6	1. College of Science, University of Santo Tomas, España Blvd., Manila 1008
7	Philippines
8	2. Department of Clinical Epidemiology, College of Medicine, University of the
9	Philippines-Manila, Pedro Gil Street, Ermita, Manila, 1000 Philippines
10	3. Institute of Clinical Epidemiology, National Institutes of Health, University of
11	the Philippines-Manila, Pedro Gil Street, Ermita, Manila, 1000 Philippines
12	4. Institute for Neurosciences, St. Luke's Medical Center, 279 E. Rodriguez Sr.
13	Ave, Quezon City, 1112 Philippines
14	5. The Graduate School, University of Santo Tomas, España Blvd., Manila 1008
15	Philippines
16	6. St. Luke's Medical Center College of Medicine - William H. Quasha Memorial,
17	279 E Rodriguez Sr. Ave, Quezon City, 1112 Metro Manila
18	
19	* Corresponding author: <a href="mailto:adligsay@ust.edu.ph">adligsay@ust.edu.ph</a> ; College of Science, University of
20	Santo Tomas, España Blvd., Manila 1008 Philippines
21	
22	
23	
24	
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Butardo, et al, COVID and Brain Fog

2

26

#### ABSTRACT

Objective: The systematic review aims to examine the association between COVID 19 and cognitive dysfunction, including the link between the severity of COVID-19
 and the occurrence of cognitive impairment and the potential pathophysiological
 mechanisms related to brain fog among COVID-19 patients.

Methods: PubMed, Oxford University Press, ProQuest Health and Medical Complete, ScienceDirect, Ovid, HERDIN, Google Scholar, and Cochrane Library databases were accessed to retrieve literature using the PRISMA guidelines.

34 **Results:** After critical appraisal, thirteen full journal articles were included in the study. The studies showed the most frequent cognitive impairment are attention, 35 memory, and executive function in COVID-19 patients. Compared with healthy 36 37 controls (HC) in 3 out of 4 studies, cognitive impairment was only evident in COVID-19 patients. Furthermore, two studies showed no correlation between brain fog and 38 depression, and five studies showed a link between the severity of COVID-19 39 40 infection and cognitive impairment. Cases ranging from mild to severe illness presented manifestations of brain fog. However, a disparity in the evidence of the 41 pathophysiology of COVID-19 and cognitive dysfunction exists, prompting the need 42 to investigate further. Additionally, recent studies provide insufficient evidence for 43 direct central nervous system invasion, and there are emerging studies that contrast 44 45 the presumed pathogenesis of neurological complications from neuroinflammation.

Conclusion: There is an association between COVID-19 and cognitive dysfunction.
 Manifestation of cognitive dysfunction is present regardless of illness severity.
 Moreover, there are existing pathophysiological mechanisms of the Coronavirus that
 lead to cognitive dysfunction in COVID-19 patients; however, additional studies are
 required to substantiate such mechanisms further.

Butardo, et al, COVID and Brain Fog

3

# 51 **PROSPERO Registration Number:** CRD42022325669

52 **Keywords:** *brain fog, cognitive dysfunction, COVID-19, disease severity,* 53 *neuroinflammatory processes, pathophysiology, SARS-CoV-2 infection* 

54

55

# INTRODUCTION

With millions of Coronavirus (COVID-19) cases worldwide, it is becoming 56 57 apparent that more people are experiencing neurological symptoms associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. For this 58 59 reason, researches into the putative link between SARS-CoV-2 and neurological manifestations continue to grow (Desai et al., 2021; Ghannam et al., 2020; 60 Guadarrama-Ortiz et al., 2020). Cognitive dysfunction, also known as brain fog, is 61 62 defined as the decrements in the cognitive status during continuous mental activity (García-Sánchez et al., 2022). Brain fog as a general term can present as confusion, 63 difficulty finding the appropriate words, disorientation, memory problems, altered 64 mental status, and trouble concentrating (Altuna et al., 2021; Asadi-Pooya et al., 2022; 65 Hampshire et al., 2021). Such decline can be measured using various neurocognitive 66 67 assessments that can either reveal a cognitive impairment with a certain severity or discern which specific cognitive domain is significantly affected. According to the 68 Montreal Cognitive Assessment (MoCA) test, the cognitive domains include 69 orientation, attention, language, visuospatial function, memory, and executive function 70 71 (Julayanont & Nasreddine, 2017).

Gustatory and olfactory impairments are the most frequent sudden neurologic manifestations of COVID-19 associated with the peripheral nervous system (PNS), which occur in the early stages of SARS-CoV-2 infection (Cooper et al., 2020; Lechien et al., 2020; Salcan et al., 2021). These sensory impairments entail that SARS-CoV-2

#### Butardo, et al, COVID and Brain Fog

4

is afflicting the nervous system (ladecola et al., 2020). The SARS-CoV-2 virus could potentially affect the gustatory system in two different ways– either by directly damaging the mucosal membrane of the oral cavity and the peripheral neuronal trajectory of the gustatory tract or by directly damaging the cranial nerves that are responsible for the sense of taste (Finsterer & Stollberger, 2020). With the presentation of anosmia in COVID-19 patients, olfactory neurons were at an incredibly high risk of injury due to the high viral load within the nasal cavity (Zou et al., 2020).

The discovery of the brain invasion of mice by the intranasal administration of 83 84 the novel coronavirus (Kumari et al., 2021) and the existing knowledge about the previous detection of other coronaviruses in human cerebrum (Cheng et al., 2020) led 85 to a hypothesis that COVID-19 infection can be linked with neurocognitive 86 87 complications. Preliminary studies suggest that cognitive deficits of hospitalized COVID-19 patients were dependent on two factors: the medical assistance they 88 received (Ferrucci et al., 2021; Hampshire et al., 2021) and the degree of inflammation 89 90 (Zhou et al., 2020); that is, severe infections are assumed to contribute to severe cognitive impairments (Beaud et al., 2021; Tay et al., 2021; Wild et al., 2021). 91 However, there are still gaps in the studies regarding how COVID-19 infection 92 increases cognitive impairment risk, severity, and progression. There is mounting 93 evidence that brain fog is among the observed neurological manifestations of COVID-94 95 19 (Whittaker et al., 2020). However, the association of the symptom, including the possible mechanisms and the potential triggers, remains unclear. Consequently, if 96 there is an association between the two, research about the extent of the impact on 97 98 cognition and the affected cognitive domains of brain fog is limited (Zhou et al., 2020). Therefore, researchers have yet to determine whether cognitive systems are equally 99 100 affected or some domains are more susceptible to SARS-CoV-2 infection. The primary

#### Butardo, et al, COVID and Brain Fog

5

101 purpose of this review is to assess cognitive dysfunction, more commonly known as "brain fog," as a symptom of COVID-19 to understand its etiology better. This 102 encompasses the mechanisms that may cause the impairment and the prevalence of 103 104 the emergent symptom. The current study also aims to determine the association between SARS-CoV-2 infection and cognitive dysfunction, elucidate the link between 105 the severity of COVID-19 infection and brain fog, and describe the potential 106 107 pathophysiological mechanisms related to cognitive dysfunction in COVID-positive individuals. This study gathered evidence that could provide clarity on the association 108 109 between brain fog and COVID-19 infection.

- 110
- 111

# METHODS

# 112 Study Setting

The study was carried out for six months (July to December 2021). Database 113 searching was the initial step for identifying reports. Search strategies were employed, 114 115 and primary identified records were based on the titles, database availability, and abstracts. Reviewers evaluated these based on predetermined inclusion criteria. Once 116 reports have passed the inclusion criteria, a full-text report was obtained to assess its 117 eligibility against the inclusion criteria further. Irretrievable full-text reports were 118 119 excluded. More specifically, a population, phenomenon of interest, and context (PICO) 120 approach was utilized to generate a sequence of terms (Lockwood et al., 2015; Munn 121 et al., 2018).

# 122 Eligibility Criteria/ Criteria for Considering Studies for this Review

123 Types of Studies

124 The studies included in this systematic review were observational studies, 125 including case reports, case series, cross-sectional studies, case-control studies, and

#### Butardo, et al, COVID and Brain Fog

6

126 cohort studies. In addition, reports focusing on individuals with COVID-19 who suffer
127 from brain fog were included. Only articles in the English language restriction were
128 imposed.

129 Types of Participants

Participants included in the study were patients who tested positive for COVID-131 19 through a Reverse Transcription Polymerase Chain Reaction (RT-PCR), antigen 132 test or SARS-CoV-2-specific immunoglobulin G (IgG) in serum and experienced 133 cognitive dysfunction. All COVID-19 positive patients were included regardless of sex, 134 race, ethnicity, and age. In addition, healthy, non-COVID-19 patients were also 135 included for comparison.

136 Types of Phenomena of Interest and Context

This systematic review's main phenomena of interest included the manifestation of brain fog in COVID-19 patients and non-COVID-19 patients. Therefore, studies focusing on the link between COVID-19 severity and occurrence of brain fog and potential mechanisms that cause cognitive dysfunction as a symptom of COVID-19 were also included.

# 142 Search Methods for Identification of Studies

143 Information Sources

The following databases were used to identify completed studies until December 2021: PubMed, Oxford University Press, ProQuest Health and Medical Complete, ScienceDirect, Ovid, HERDIN, Google Scholar, and Cochrane Library. Ongoing studies were recognized; however, these studies were not included in the systematic review. In addition, a date restriction was set for identifying studies: studies since the start of the COVID-19 pandemic, January 2020 up to December 2021, were

#### Butardo, et al, COVID and Brain Fog

7

included in this systematic review. Furthermore, English language restriction wasimposed.

152 Search Strategy

The electronic literature search included the following key terms: COVID-19, SARS-CoV-2, neurocognitive impairment, brain fog, confusion, poor concentration, memory problems, brain fog pathophysiology, neurological mechanism, and cognitive dysfunction. Moreover, the Boolean search strategy ("AND," "NOT," "AND NOT," "OR") was employed to identify studies using the key terms. The search strategy for databases can be found in online Supplemental Appendix A.

159 Selection Process

Authors independently searched for studies that were included in the systematic review. The initial selection of studies consists of the examination of the titles, abstracts, and full-text, if available. Inclusion criteria implemented were observational studies on individuals with COVID-19 who experience cognitive dysfunction. The authors created the final list of included studies. Any disagreements that arose during the appraisal process were settled by discussing with another author.

166 Assessment of Risk of Bias in Individual Studies

Three authors (MFDC, TRFM, and OKSD) independently evaluated the risk of 167 168 bias in each study. A fourth (NDB) and fifth (AMOD) author was assigned to resolve 169 disagreements in assessments. To assess bias in included studies, they were segregated into observational studies such as case reports, case series, cross-170 sectional studies, case-control studies, and cohort studies. The risk of bias in the 171 172 included studies was assessed using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (Vandenbroucke et al., 173 174 2007). The risk of bias was scored as "low," "moderate," or "high" risk. The overall

#### Butardo, et al, COVID and Brain Fog

8

quality of each study was given a rating based on the score from the STROBEstatement. Furthermore, only studies with a low-risk rating were included in the study.

#### 177 Data analysis and presentation

Formatted according to the extraction tool used to extract the data, an MS Excel spreadsheet was used to tabulate results for representation of results. The characteristics of the included articles were described, which were previously discussed and agreed upon within the study team.

#### 182 Evidence Synthesis

A narrative synthesis of overall evidence was undertaken by comparing and contrasting the data to express and synthesize the results of the included studies. Development of a preliminary synthesis, exploration of the relationships within and between studies, and the determination of the robustness of the synthesis were the three stages of the narrative synthesis undertaken by the research team (Popay et al., 2006). Data of the included studies were qualitatively described and presented. The authors frequently met to discuss the results and reach a consensus on the findings.

190

### RESULTS

# 191 **Description of the Studies**

### 192 Literature Search

Two hundred eighty-nine studies were identified after a comprehensive search through databases (PubMed, ProQuest, Oxford University Press, ScienceDirect, Cochrane Library, Google Scholar, JSTOR, and Herdin). Duplicate records (n=12) were removed based on their titles. After initial screening, 177 studies were excluded due to differences in study design (*e.g.*, review paper, narrative review, hypothesis/theory article and chart review) based on the title and abstract. In addition, 15 articles were not retrieved because the study is ongoing. A total of 85 full-text

#### Butardo, et al, COVID and Brain Fog

9

studies were assessed for eligibility. After critical appraisal, 13 studies were included
in the final systematic review. An adapted PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow chart of the study selection is presented
in Fig. 1.

204 Included Studies

Characteristics of the included studies are tabulated in Table 1. The age of the 205 206 study participants in the included studies was greater than 16 years old. All study 207 participants were diagnosed with COVID-19 through various diagnostic tests such as 208 SARS-CoV-2 RT-PCR of a nasopharyngeal swab, SARS-CoV-2 antibody testing (e.g., SARS-CoV-2-specific IgG in serum), rapid antigen test, and polymerase chain 209 reaction (PCR) test for SARS-CoV-2 in upper and/or lower airway samples. 210 211 Participants in 4 included studies were assessed during COVID-19 infection, seven during post-COVID-19 infection, 4 had follow-ups, and one examined patients post-212 mortem. The duration of the follow-ups in the included studies ranges from 2 to 4 213 214 months. Out of the 13 included observational studies, 1 is a case series, 1 is a case report, 6 were cross-sectional studies, and 5 were cohort studies. 215

## 216 *Excluded Studies*

A total of 276 studies were excluded from the list of included studies due to the following reasons: different study design (n=179), irrelevance to the systematic review (n=59), unavailability of the full-text article (n=16), duplications (n=13), and focused on the psychological aspect (n=9).

#### 221 Risk of Bias in Included Studies

Observational studies were evaluated based on ten domains: Introduction - (1)
Objectives; Methods - (2) Participants; Results - (3) Participants, (4) Descriptive Data,
(5) Outcome Data, and (6) Main Results; Discussion - (7) Key Results, (8) Limitations,

#### Butardo, et al, COVID and Brain Fog

10

(9) Interpretation, and (10) Generalizability. Of the 13 included observational studies,all were assessed as low risk of bias.

#### 227 Qualitative Results

Eleven studies focused on the association between COVID-19 and brain fog, five (5) studies identified the link between the severity of COVID-19 and the occurrence of cognitive dysfunction, and seven (7) studies described the possible pathophysiological mechanisms related to brain fog in COVID-19 patients.

# 232 Association between SARS-CoV-2 infection and neurocognitive dysfunction

233 The prospective cohort study conducted two MoCA tests with mean scores of 19.1 and 23.4 on the first and second exams, respectively (Blazhenets et al., 2021). 234 The average scores showed significant improvement on the second exam. However, 235 236 the MoCA performance of the second exam was still within the range of mild cognitive impairment (MCI). In a cross-sectional study, the average MoCA score of the COVID-237 19 patients was significantly lower than the healthy controls (Ortelli et al., 2021). In 238 239 addition, the severity of cognitive impairment was mentioned in a study (Hosp et al., 2021) wherein 54% (14/26) of the participants were mild to moderately impaired, 240 whereas 15% (4/26) were severely impaired (see Table 2 for details). 241

Seven of the included studies reported domain-specific cognitive deficits. The prospective cohort assessed all six (6) cognitive domains that showed an insignificant decline in orientation and attention domains with 6.00 and 5.13 scores, respectively (Blazhenets et al., 2021). However, the MoCA domain scores on language (3.88), visuospatial function (3.13), memory (2.25), and executive function (2.50) revealed significant cognitive deficits.

Another cohort study also utilized the MoCA test (Hosp et al., 2021). The MoCA domain scores in this study revealed an impairment in executive function, visuospatial

#### Butardo, et al, COVID and Brain Fog

11

function, memory, and attention. The two other domains, language, and orientation,
were not impaired. An extended neuropsychological test battery confirmed the deficit
in executive function and memory, but not in attention (Hosp et al., 2021).

253 In a cross-sectional study, two cognitive domains such as attention and executive function, were assessed using three subtests of MoCA and Frontal 254 Assessment Battery (FAB), respectively (Ortelli et al., 2021). The reaction time (RT) 255 256 of the COVID-19 patients in each subtest of MoCA was compared with that of the 257 healthy controls. In two of the subtests, namely Stroop Interference Task (SIT) and 258 Navon Task (NT), the RTs were significantly longer in the patients than in the healthy controls (HC). In contrast, the RTs of the patients and the healthy controls in the 259 Vigilance Task (VT) did not have a significant difference. Furthermore, significantly 260 261 lower FAB scores were observed in COVID-19 patients than in the healthy controls indicating an executive function deficit (Ortelli et al., 2021). 262

Another study also utilized subtests of MoCA such as the Trail Making Test 263 264 (TMT), Sign Coding Test (SCT), Continuous Performance Test (CPT), and Digit Span Test (DST) that revealed significant differences in the attention domain and no 265 significant differences in executive function, visuospatial function, and memory 266 between COVID-19 patients and healthy controls (Zhou et al., 2020). Meanwhile, in a 267 268 cohort study, a neuropsychological assessment battery revealed specific cognitive 269 deficits in non-ICU and post-ICU COVID-19 patients (Vannorsdall et al., 2022). Both groups showed significant cognitive impairment in three cognitive domains, namely 270 executive function, language, and memory but not in attention. 271

A different cognitive function assessment tool was used in another cohort study (Graham et al., 2021). In this study, the National Institutes of Health (NIH) Toolbox v2.1 instrument revealed a mild to moderate cognitive impairment in both COVID-19

#### Butardo, et al, COVID and Brain Fog

12

patients and healthy controls; however, it did not show any significant difference
between the Toolbox T-scores of the two groups.

A Modified Telephone Interview for Cognitive Status (TICS-M) is another screening tool for MCI used in another study (Woo et al., 2020). Cognitive deficits in orientation, memory, attention, and language in post-COVID-19 patients and healthy controls were reported. It was also revealed that the scores of the patients in three domains, specifically memory, attention, and language, were significantly lower than the healthy controls (Woo et al., 2020).

283 Moreover, a cross-sectional study involving 199 patients from Lima, Peru, described the relationship between mild to moderate COVID-19 infection and 284 neurological symptoms, wherein 7 out of 199 patients (3.5%) presented impaired 285 286 consciousness (M. H. C. Garcia et al., 2021). Meanwhile, in another study, 23 patients who had severe to critical COVID-19 were analyzed (Puchner et al., 2021). A 287 neuropsychological evaluation was conducted on 14 out of the 23 patients, and four 288 289 patients (29%) were found to have cognitive dysfunction in memory, executive function, and attention (Puchner et al., 2021). In addition, a case study reported a 290 patient who tested positive for SARS-CoV-2 and did not have any neurologic or 291 psychiatric evaluation history. The patient was evaluated using a neuropsychological 292 293 battery test, including the Global Deterioration Scale (GDS), California Verbal 294 Learning Test (CVLT), FAB, and TMT. The neurological battery tests suggested cognitive impairment (FAB score of 16; GDS stage 3) in executive function, 295 concentration, and memory. At the patient's follow-up, no cognitive impairment was 296 297 identified (FAB score of 13; GDS stage 1) (Yesilkaya et al., 2021).

Fourteen COVID-19 patients underwent hospital anxiety and depression scale (HADS-D) that revealed no significant increase in their anxiety and depression

#### Butardo, et al, COVID and Brain Fog

13

300 symptoms despite detecting cognitive deficits in memory and executive 301 functions.(Puchner et al., 2021) A similar study that utilized the Patient Health 302 Questionnaire - 9 (PHQ-9) Depression Scale revealed no significant correlation 303 between depression and cognitive dysfunction.(Woo et al., 2020) Meanwhile, one 304 study used the Beck Depression Inventory (BDI), wherein scores of COVID-19 305 patients and healthy controls had a significant difference (Ortelli et al., 2021).

306 *Elucidating the link between disease severity of COVID-19 infection and the* 307 *manifestation of cognitive dysfunction* 

308 The National Institute of Health (NIH) established a classification for the clinical 309 spectrum of SARS-CoV-2 infection. Patients with COVID-19 may be grouped according to illness severity: asymptomatic or presymptomatic, mild, moderate, 310 311 severe, and critical illness (Health, 2020). Increasing evidence suggests that the 312 severity of SARS-CoV-2 infection is linked with the occurrence of cognitive dysfunction in COVID-19 patients. After evaluation of retrieved and appraised journals, five studies 313 314 correlate with this hypothesis (see Table 3). In the cross-sectional study examining cerebrospinal fluid (CSF) of 18 COVID-19 subjects with neurological complications, 315 44% (8) were classified as critical, 28% (5) as severe, 22% (4) as moderate, and one 316 patient as mild illness (M. A. Garcia et al., 2021). This review shows that across the 317 318 case of 18 COVID-19 patients, all exhibited cognitive dysfunction regardless of case 319 severity. Furthermore, a cohort study conducted among patients of the John Hopkins Post-Acute COVID-19 Team (PACT) Pulmonary Clinic reveals that out of 82 patients 320 classified for critical illness, 67% (54) demonstrated abnormally low cognitive scores 321 322 (≥1 deviation from published age-adjustive normative means) and is correlated to mild/moderate or severe range of cognitive impairment (Vannorsdall et al., 2022). In 323 324 addition, the prospective-single center study involved 19 patients with a distribution of

#### Butardo, et al, COVID and Brain Fog

14

11% (2) having a mild illness, 21% (4) having a moderate illness, another 21% (4) 325 having a severe illness, and 47% (9) having critical illness severity (2021) were 326 reported (Virhammar et al., 2021). Report also showed that 2 out of 9 critically ill 327 patients manifested cognitive dysfunction, 2 out of 4 severely ill patients showed 328 altered mental status, and 2 out of 4 moderately ill patients exhibited confusion and 329 altered mental status (Virhammar et al., 2021). Findings show that there is no specific 330 pattern for COVID-19-related cognitive dysfunction. Lastly, a cross-sectional study 331 332 conducted at the University Medical Center Hamburg-Eppendorf involved 18 patients 333 in either mild or moderate severity (Woo et al., 2020). Cognitive deficiencies were present among the involved patients: 9 (50%) reported having attention deficiency, 8 334 (44.4%) suffered from concentration deficits, 8 (44.4%) experienced short-term 335 336 memory deficiency, and 5 (27.8%) had trouble finding words. Results from 18 patients 337 impacted with COVID-19 were compared to 10 healthy non-COVID patients. Findings also show that COVID-19 neurological sequelae are independent of hospitalization 338 339 and illness severity (Woo et al., 2020).

# 340 Possible pathophysiological mechanisms leading to cognitive dysfunction

Seven studies analyzed cognitive dysfunction in COVID-19 patients on a 341 molecular level and their potential pathogenesis. One study examined serum pro-342 343 inflammatory markers (interleukin-2 (IL-2), IL-4, IL-6, IL-10, tumor necrosis factor-a 344  $(TNF-\alpha)$ , interferon-y (IFN-y), and C-reactive protein (CRP) (Zhou et al., 2020). However, their findings revealed no significant correlation between the inflammatory 345 markers and the cognitive function assessment results from the Trail Making Test, 346 347 Sign Coding Test, and Digital Span Test. In contrast, all the 29 post-COVID-19 patients showed a trend of significant difference for lower reaction time in the first and 348 349 second parts of CPT and a lower correct number in the second part of CPT than the

#### Butardo, et al, COVID and Brain Fog

15

350 29 healthy controls. The serum C-reactive protein level and reaction time in the Continuous Performance Test are positively correlated. Moreover, 11 post-COVID-19 351 patients demonstrated hyper-inflammation, evidenced by elevated C-reactive protein 352 353 (CRP) and interleukin-6 serum levels (Ortelli et al., 2021). The remarkable proinflammatory state induced by SARS-CoV-2 in all 4 cases and the cessation of 354 carbidopa-levodopa in one patient case described in another study has been 355 356 postulated to convey a dysregulated immune response and a potential precipitant of 357 the abrupt mental confusion and emotional disarray (Beach et al., 2020).

358 One study analyzed the CSF of 19 patients with mild to critical COVID-19. Only one (5%) was positive for SARS-CoV-2. The analysis includes biomarkers of central 359 nervous system injury (neurofilament light chain (NfL) protein, glial fibrillary acidic 360 361 protein (GFAp), and total tau (T-tau), and found increased CSF levels of NfL (63%), total tau (37%), and GFAp (16%). The amount of CSF NfL was higher in patients with 362 central neurological symptoms, and the elevated level was associated with the 363 364 severity of the disease, time spent in critical care, and level of consciousness (Virhammar et al., 2021). 365

Another study evaluated fluorodeoxyglucose (FDG)-positron emission 366 tomography (PET) images of 8 COVID-19 patients (post-infection) and the MoCA 367 scores to assess neuronal damage or synaptic dysfunction distribution (Blazhenets et 368 369 al., 2021). They discovered that after the patients are no longer infectious and in the chronic stage (about six months after symptom onset), their impaired neocortical 370 glucose metabolism can return to normal levels, evidence of reversibility, which is 371 372 critical for the pathophysiology of cognitive deficit. In the FDG PET scans of another study, 10 of the 15 patients had abnormal findings (Hosp et al., 2021). According to 373 374 the observer, 10 of the subjects had cortical hypometabolism, with 2 cases having

#### Butardo, et al, COVID and Brain Fog

16

375 striatal hypermetabolism. Likewise, the second observer noted cerebral hypometabolism in 6 out of 9 subjects. Striatal hypermetabolism is present in the other 376 three cases. In addition, their findings demonstrated a highly significant linear 377 378 association between MoCA and PET, with more robust pattern expression being related to poorer cognitive function. The same study found oligoclonal bands present 379 with identical electrophoretic patterns in the serum in one patient but unremarkable 380 381 protein and IgG levels in 4 out of 29 who agreed to undergo CSF analysis. Moreover, 382 all CSF samples tested negative for SARS-CoV-2 (Hosp et al., 2021).

In a case study, the CSF analysis through lumbar puncture is unremarkable. The N-acetylaspartate (NAA), glutamate, and glutamate/glutamine ratio were measured using MR-spectroscopy and bilateral DLPFC. A week and three months following the initial diagnosis of SARS-CoV-2 infection, substantial increases in glutamate, glutamine, and NAA levels were discovered during follow-up, suggesting that the glutamatergic pathway might be implicated in the pathogenesis of cognitive impairment (Yesilkaya et al., 2021).

390

#### DISCUSSION

All studies that utilized the MoCA test showed MCI following COVID-19 391 infection. An included study reported a more severe global cognitive impairment 392 393 among COVID-19 patients than healthy controls (Ortelli et al., 2021). Among the 394 cognitive domains, attention, executive function, and memory are most likely to be impaired. These were also the domains that frequently showed significant differences 395 between COVID-19 and non-COVID-19 patients in a recent study (Crivelli et al., 2022). 396 397 This observation is congruent with another study reporting that the exact cognitive domains, except for memory, seem prone to impairments (Daroische et al., 2021). On 398 the other hand, results on language, orientation, and visuospatial function varied in 399

#### Butardo, et al, COVID and Brain Fog

17

the included studies. This inconsistency may be due to the apparent heterogeneity inthe tests used, time of evaluation, eligibility criteria, and the presentation of results.

Majority of the included studies utilized the MoCA test (n = 5), followed by NIH 402 403 Toolbox (n = 1) and TICS-M (n = 1). Different tests with varying total scores, sensitivity, and specificity in comparing study populations can be attributed to the contradictory 404 results. For instance, one study used three tests, SIT, NT, and VT, all assessed the 405 406 attention domain and discovered that only SIT and NT showed significantly different RTs between COVID-19 and healthy controls (Ortelli et al., 2021). However, the 407 408 difference in VT was not statistically different. Furthermore, some studies either did not specify or utilized different cut-off scores. Two studies used the same test and total 409 score. Still, different cut-off values in assessing visuospatial function, thereby affecting 410 411 the consistency of the interpretation (Blazhenets et al., 2021; Hosp et al., 2021). This emphasizes the need for a standardized and accurate test specific to each cognitive 412 domain. 413

414 A prospective cohort study with 31 participants showed a better MoCA performance of COVID-19 patients at the chronic stage than at the subacute stage 415 416 (Blazhenets et al., 2021). The authors provided evidence that supports the association between COVID-19 infection and cognitive dysfunction, and these deficits can still be 417 418 measured six months after symptom onset of COVID-19. However, only eight patients 419 underwent a second MoCA examination at the chronic stage of the disease. Similarly, 420 another study reported that only one-tenth of the patients had cognitive dysfunction at the 6-month follow-up (Nalbandian et al., 2021). With that, the different assessment 421 422 times of the included studies could be the result of the inconsistency. More research using the same methodology is necessary to evaluate the time frame of cognitive 423 dysfunction after COVID-19 infection. 424

#### Butardo, et al, COVID and Brain Fog

18

Several studies showed the comparison of results between COVID-19 and nonCOVID-19 patients (healthy controls). Three of the four studies used HC and reported
a cognitive impairment only in COVID-19 patients (Ortelli et al., 2021; Woo et al., 2020;
Zhou et al., 2020). A similar review reported that its included studies had significantly
more cases of cognitive impairment in COVID-19 patients than in HC (Daroische et al., 2021).

431 Of all included studies, only three studies measured depression, two of which stated no correlation between depression and cognitive dysfunction. However, one 432 433 study reported a significant difference in depression between COVID-19 patients and HC (Ortelli et al., 2021). Previous studies hypothesized that cognitive dysfunction and 434 depression was bi-directional (Miskowiak et al., 2021; Vinkers et al., 2020). Severe 435 436 cognitive dysfunctions may produce more depression because of increased difficulty 437 in daily life functions. In addition, more symptoms of depression can affect the performance in cognitive tests (Miskowiak et al., 2021). Therefore, there should be 438 439 more significant consideration of mood and cognitive symptoms following COVID-19 infection. 440

Emerging reports indicate that a large population suffers from cognitive 441 dysfunction due to COVID-19 infection. Results from the selected studies (Table 3) 442 443 showed that cognitive dysfunction is present among patients characterized by mild, 444 moderate, severe, and critical illnesses. According to a report, cognitive impairments were most prevalent in hospitalized patients (Hampshire et al., 2021). However, non-445 hospitalized patients also exhibited cognitive dysfunction relating to COVID-19 446 447 infection. A recent study stated evidence of cognitive deficits in patients classified with mild to moderate illness (Del Brutto et al., 2021). Cases exhibiting severe illness also 448 provide proof of cognitive deficit (Hampshire et al., 2021; Negrini et al., 2021). 449

#### Butardo, et al, COVID and Brain Fog

19

450 Additionally, severe infections are assumed to contribute to severe cognitive impairments (Beaud et al., 2021; Tay et al., 2021; Wild et al., 2021). Moreover, another 451 study reported that critically ill patients presented long-lasting complaints of inability to 452 think and concentrate (brain fog) (Asadi-Pooya et al., 2022). In contrast with the 453 current study results, other studies revealed that cognitive deficits were also observed 454 in asymptomatic/presymptomatic cases (Amalakanti et al., 2021; Huang et al., 2021; 455 456 Tenforde et al., 2020). Therefore, regardless of the intensity of clinical manifestations 457 of COVID-19, patients may still develop brain fog; however, take into account that the 458 link between the severity of COVID-19 and severity of brain fog was not elucidated. The correlation between the severity of COVID-19 disease & severity of cognitive 459 dysfunction remains inconclusive due to a lack of studies, variation of patient 460 characteristics, and breadth and depth of cognitive assessment. The establishment of 461 standardized tests for obtaining cognitive scores should be developed to represent a 462 463 normative data set to analyze the correlation of severity scale.

Out of 13 studies, only three tested for the presence of SARS-CoV-2 in the 464 CSF. No evidence of viral RNA in the CSF was reported (M. A. Garcia et al., 2021). 465 Likewise, all tested negative among 4 out of 29 patients who underwent lumbar 466 puncture (Hosp et al., 2021). On the other hand, 1 out of 19 patients tested positive 467 for SARS-CoV-2 in CSF findings (Virhammar et al., 2021). The lack of studies 468 reporting the presence of viral RNA in the CSF leads to inadequate evidence of 469 SARS-CoV-2 neuroinvasion, suggesting that it is not the primary pathogenic 470 mechanism in most cases. The NfL protein is an indicator of neuroaxonal damage. 471 Recent research of 544 Mexican Americans found that NfL had a detrimental influence 472 on processing speed, attention, executive skills, and delayed recognition memory in 473 normal and mild cognitive impairment groups, suggesting its significance as a marker 474

#### Butardo, et al, COVID and Brain Fog

20

475 of cognitive impairment and early cognitive impairment changes (Hall et al., 2020). In a previous study that used a community-based population of non-cognitive impairment 476 participants, CSF NfL is a better predictor of cognitive deterioration than other CSF 477 478 markers of neurodegeneration (Mielke et al., 2021). Another study elaborates on the association of biomarkers such as t-tau with cognitive decline (Chen et al., 2021). The 479 findings showed that higher levels of plasma biomarkers (i.e., AB42, t-tau, and AB42 480 481 × t-tau) were found in participants who showed a cognitive decline (the declined group) compared to those who did not (the stable group) and were associated with lower 482 483 episodic verbal memory performance at baseline and a more significant annual decrease in MMSE score (Chen et al., 2021). 484

Instead of the classic post-viral syndrome, cognitive impairment may be a 485 486 distinct post-COVID-19 manifestation caused by altered neuronal signaling in the brain due to the immune response triggered by the virus. However, there is no evidence of 487 a link between inflammatory responses during acute infection (Woo et al., 2020). The 488 489 presence of oligoclonal bands in one patient might be similar to the association of these bands in cognitive decline in other inflammatory and neurodegenerative 490 491 diseases of the central nervous system like multiple sclerosis (Giedraitiene et al., 2021). 492

This study is limited by the number of studies available with the appropriate parameters. Most studies available were systematic and meta-analysis studies and observational studies that were inconclusive or unrelated to the topic of interest. Moreover, the majority of the excluded studies focused on neurological manifestations in general and did not necessarily mention cognitive dysfunction. Another limitation is the possibility that some relevant studies were not taken into account because they have been published in languages other than English (e.g., Chinese). We also did not

#### Butardo, et al, COVID and Brain Fog

21

500 have access to some other databases that may store some articles on COVID-19 and 501 cognitive dysfunctions. And lastly, there could be some other studies on this theme in 502 the literature that skipped our attention and analyses. However, a comprehensive 503 search strategy that covers a broad range of evidence was implemented.

This systematic review gathered evidence that could provide clarity on the 504 association between brain fog and COVID-19 infection. The information acquired in 505 506 this study may help re-evaluate the impact of the virus. Furthermore, the use of the 507 data gleaned from this analysis may assist in earlier treatment, allowing physicians 508 and clinicians to manage the neurological manifestation effectively. Additionally, this 509 will aid in the development of various therapeutic strategies to support COVID-19 patients in recovering from impaired cognitive capacity. Finally, the analysis of such 510 511 data could provide an insight into the challenges that this virus could cause people in their prime years, particularly those in the workforce. 512

513

### CONCLUSION

514 Attention, memory, and executive function were the most frequently affected cognitive domains in COVID-19 patients. There was also a significant difference in the 515 516 neuropsychological assessment scores between COVID-19 patients and HC. Interestingly, results from the included studies showed no correlation between 517 518 cognitive dysfunction and depression. Increasing evidence suggests that cognitive 519 dysfunction due to COVID-19 is manifested across disease severity ranging from 520 asymptomatic to critical illness. The interplay of physical and cognitive impairments may lead to functional problems inhibiting health-related standards of life. The 521 522 knowledge gained from this study may be used to improve the implementation of comprehensive treatment modalities and rehabilitation throughout the COVID-19 care 523 continuum to remove such barriers and restore the meaningful lives of patients brought 524

#### Butardo, et al, COVID and Brain Fog

22

525 about by brain fog. The findings from this systematic review indicate multiple potential pathophysiological mechanisms related to cognitive dysfunction in COVID-positive 526 individuals. Neuroinflammation is one of the mechanisms that have led to cognitive 527 528 dysfunction based on the studies obtained. Neuroinflammation in the NFL protein and inflammatory levels indicated by CRP provide further insight into the pathophysiology 529 that could lead to cognitive dysfunction. The evidence appears to be contrasting; 530 531 however, from what was gathered, the CNS invasion is not the primary pathological 532 mechanism due to the lack of studies that portray the presence of SARS-COV-2 533 concerning said mechanism. It is also suggested that neuroinflammation is not substantial enough even with the rising levels of pro-inflammatory markers due to the 534 lack of value in numbers. Therefore, more studies are needed to substantiate these 535 536 pathophysiological mechanisms further.

# 537 Acknowledgment

538 The authors acknowledge the University of Santo Tomas College of Science, 539 especially the Department of Biological Sciences, for the support and assistance.

## 540 Authors' Contributions

ADL conceptualized the study following discussion with JCD. MFDC, TRFM, OKSD, 541 NDB, and AMOD designed the protocol, with feedback from ADL, ESB, ZGR, and 542 543 JCD. MFDC, TRFM, OKSD, NDB, and AMOD ran the database search and oversaw 544 the search, screening, full-text review and data extraction process. ZGR, ESB and ADL drafted the manuscript. All authors reviewed the draft, provided critical review 545 and read and approved the final manuscript. The corresponding author, as guarantor, 546 547 accepts full responsibility for the finished article has access to any data and controlled the decision to publish. The corresponding author attests that all listed authors meet 548 549 the authorship criteria and that no others meeting the criteria have been omitted.

Butardo, et al, COVID and Brain Fog

- 550 **Competing interests :** None declared.
- 551 Funding Statement: The study did not receive any research grants for its
- 552 implementation.

# 553 Data availability statement

- 554 Data are available on reasonable request. Extracted data are available on request to
- 555 the corresponding author.
- 556 **Registration:** This study is registered in PROSPERO (International Prospective
- 557 Register for Systematic Reviews) as CRD42022325669.
- 558 Author Note: If there is a need to amend the study protocol or results, the date of
- each amendment and the reason for the change will be described.

# 560 Ethics statements

- 561 Patient consent for publication
- 562 Not applicable.
- 563 Ethics approval
- 564 Ethical approval was not required for this systematic review, since all data came from
- information freely available in the public domain (i.e., published articles or conference

abstracts). This study does not involve human participants.

567

## 568 **REFERENCES**

- 569 ALTUNA, M., SÁNCHEZ-SAUDINÓS, M. B., & LLEÓ, A. (2021). Cognitive
- 570 symptoms after COVID-19. *Neurology Perspectives*, *1*, S16-S24.
- 571 AMALAKANTI, S., AREPALLI, K. V. R., & JILLELLA, J. P. (2021). Cognitive
- 572 assessment in asymptomatic COVID-19 subjects. Virusdisease, 32(1), 146-
- 573 149.

Butardo, et al, COVID and Brain Fog

574 ASA	DI-POOYA,	A. A	., AKBARI,	A., EMA	λMΙ, Α., Ι	LOTFI, M.,
---------	-----------	------	------------	---------	------------	------------

- 575 ROSTAMIHOSSEINKHANI, M., NEMATI, H., BARZEGAR, Z., KABIRI, M.,
- 576 ZERAATPISHEH, Z., & FARJOUD-KOUHANJANI, M. (2022). Long COVID
- 577 syndrome-associated brain fog. *Journal of Medical Virology*, 94(3), 979-984.
- 578
- 579 BEACH, S. R., PRASCHAN, N. C., HOGAN, C., DOTSON, S., MERIDETH, F.,
- 580 KONTOS, N., FRICCHIONE, G. L., & SMITH, F. A. (2020). Delirium in
- 581 COVID-19: a case series and exploration of potential mechanisms for central
- 582 nervous system involvement. *General hospital psychiatry*, 65, 47-53.
- 583 BEAUD, V., CROTTAZ-HERBETTE, S., DUNET, V., VAUCHER, J., BERNARD-
- 584 VALNET, R., DU PASQUIER, R., BART, P.-A., & CLARKE, S. (2021). Pattern
- of cognitive deficits in severe COVID-19. *Journal of Neurology, Neurosurgery & Psychiatry*, 92(5), 567-568.
- 587 BLAZHENETS, G., SCHROETER, N., BORMANN, T., THUROW, J., WAGNER, D.,
- 588 FRINGS, L., WEILLER, C., MEYER, P. T., DRESSING, A., & HOSP, J. A.
- 589 (2021). Slow but evident recovery from neocortical dysfunction and cognitive
- 590 impairment in a series of chronic COVID-19 patients. *Journal of Nuclear*
- 591 *Medicine*, 62(7), 910-915.
- 592 CHEN, Z., CHANG, F., YAO, L., YUAN, F., HONG, J., WU, D., & WEI, Y. (2021).
- 593 Clinical significance of the cognition-related pathogenic proteins in plasma
- 594 neuronal-derived exosomes among normal cognitive adults over 45 years old
- 595 with olfactory dysfunction. *European Archives of Oto-rhino-laryngology*, 1-10.
- 596
- 597 CHENG, Q., YANG, Y., & GAO, J. (2020). Infectivity of human coronavirus in the 598 brain. *EBioMedicine*, *56*, 102799.

Butardo, et al, COVID and Brain Fog

- 599 COOPER, K. W., BRANN, D. H., FARRUGGIA, M. C., BHUTANI, S., PELLEGRINO,
- 600 R., TSUKAHARA, T., WEINREB, C., JOSEPH, P. V., LARSON, E. D., &
- 601 PARMA, V. (2020). COVID-19 and the chemical senses: supporting players

602 take center stage. *Neuron*, *107*(2), 219-233.

- 603 CRIVELLI, L., PALMER, K., CALANDRI, I., GUEKHT, A., BEGHI, E., CARROLL, W.,
- 604 FRONTERA, J., GARCÍA-AZORÍN, D., WESTENBERG, E., & WINKLER, A.
- 605 S. (2022). Changes in cognitive functioning after COVID-19: A systematic

606 review and meta-analysis. *Alzheimer's & Dementia*.

- 607 DAROISCHE, R., HEMMINGHYTH, M. S., EILERTSEN, T. H., BREITVE, M. H., &
- 608 CHWISZCZUK, L. J. (2021). Cognitive impairment after COVID-19—a review 609 on objective test data. *Frontiers in neurology*, 1238.
- 610 DEL BRUTTO, O. H., WU, S., MERA, R. M., COSTA, A. F., RECALDE, B. Y., &

611 ISSA, N. P. (2021). Cognitive decline among individuals with history of mild

612 symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested

to a population cohort. *European journal of neurology*, 28(10), 3245-3253.

- 614 DESAI, I., MANCHANDA, R., KUMAR, N., TIWARI, A., & KUMAR, M. (2021).
- 615 Neurological manifestations of coronavirus disease 2019: exploring past to 616 understand present. *Neurological Sciences*, *42*(3), 773-785.

617 FERRUCCI, R., DINI, M., GROPPO, E., ROSCI, C., REITANO, M. R., BAI, F.,

618 POLETTI, B., BRUGNERA, A., SILANI, V., & D'ARMINIO MONFORTE, A.

619 (2021). Long-lasting cognitive abnormalities after COVID-19. *Brain Sciences*,

620 *11*(2), 235.

FINSTERER, J., & STOLLBERGER, C. (2020). Causes of hypogeusia/hyposmia in
 SARS-CoV2 infected patients. *Journal of Medical Virology*.

Butardo, et al, COVID and Brain Fog

623	GARCIA, M. A., BARRERAS, P. V., LEWIS, A., PINILLA, G., SOKOLL, L. J.,
624	KICKLER, T., MOSTAFA, H., CATUREGLI, M., MOGHEKAR, A., &
625	FITZGERALD, K. C. (2021). Cerebrospinal fluid in COVID-19 neurological
626	complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no
627	evidence of cytokine storm. Journal of the neurological sciences, 427,
628	117517.
629	GARCIA, M. H. C., CHOZA, D. D. G., LINARES, B. J. S., & DIAZ, M. M. (2021).
630	Neurological manifestations of patients with mild-to-moderate COVID-19
631	attending a public hospital in Lima, Peru. ENeurologicalSci, 23, 100338.
632	GARCÍA-SÁNCHEZ, C., CALABRIA, M., GRUNDEN, N., PONS, C., ARROYO, J. A.,
633	GÓMEZ-ANSON, B., LLEÓ, A., ALCOLEA, D., BELVÍS, R., & MOROLLÓN,
634	N. (2022). Neuropsychological deficits in patients with cognitive complaints
635	after COVID-19. Brain and Behavior, 12(3), e2508.
636	GHANNAM, M., ALSHAER, Q., AL-CHALABI, M., ZAKARNA, L., ROBERTSON, J.,
637	& MANOUSAKIS, G. (2020). Neurological involvement of coronavirus disease
638	2019: a systematic review. Journal of neurology, 267(11), 3135-3153.
639	GIEDRAITIENE, N., DRUKTEINIENE, E., KIZLAITIENE, R., CIMBALAS, A.,
640	ASOKLIS, R., & KAUBRYS, G. (2021). Cognitive decline in multiple sclerosis
641	is related to the progression of retinal atrophy and presence of oligoclonal
642	bands: a 5-year follow-up study. Frontiers in neurology, 12.
643	GRAHAM, E. L., CLARK, J. R., ORBAN, Z. S., LIM, P. H., SZYMANSKI, A. L.,
644	TAYLOR, C., DIBIASE, R. M., JIA, D. T., BALABANOV, R., & HO, S. U.
645	(2021). Persistent neurologic symptoms and cognitive dysfunction in non-
646	hospitalized Covid-19 "long haulers". Annals of clinical and translational
647	neurology, 8(5), 1073-1085.

Butardo, et al, COVID and Brain Fog

648	GUADARRAMA-ORTIZ, P., CHOREÑO-PARRA, J. A., SÁNCHEZ-MARTÍNEZ, C.
649	M., PACHECO-SÁNCHEZ, F. J., RODRÍGUEZ-NAVA, A. I., & GARCÍA-
650	QUINTERO, G. (2020). Neurological aspects of SARS-CoV-2 infection:
651	mechanisms and manifestations. Frontiers in neurology, 1039.
652	HALL, J. R., JOHNSON, L. A., PETERSON, M., JULOVICH, D., COMO, T., &
653	O'BRYANT, S. E. (2020). Relationship of neurofilament light (NfL) and
654	cognitive performance in a sample of Mexican Americans with normal
655	cognition, mild cognitive impairment and dementia. Current Alzheimer
656	Research, 17(13), 1214-1220.
657	HAMPSHIRE, A., TRENDER, W., CHAMBERLAIN, S. R., JOLLY, A. E., GRANT, J.
658	E., PATRICK, F., MAZIBUKO, N., WILLIAMS, S. C., BARNBY, J. M., &
659	HELLYER, P. (2021). Cognitive deficits in people who have recovered from
660	COVID-19. EClinicalMedicine, 39, 101044.
661	HEALTH, N. I. O. (2020). Management of persons with COVID-19. COVID-19
662	Treatment Guidelines.
663	HOSP, J. A., DRESSING, A., BLAZHENETS, G., BORMANN, T., RAU, A.,
664	SCHWABENLAND, M., THUROW, J., WAGNER, D., WALLER, C., &
665	NIESEN, W. D. (2021). Cognitive impairment and altered cerebral glucose
666	metabolism in the subacute stage of COVID-19. Brain, 144(4), 1263-1276.
667	
668	HUANG, Y., PINTO, M. D., BORELLI, J. L., MEHRABADI, M. A., ABRIHIM, H.,
669	DUTT, N., LAMBERT, N., NURMI, E. L., CHAKRABORTY, R., & RAHMANI,
670	A. M. (2021). COVID symptoms, symptom clusters, and predictors for
671	becoming a long-hauler: looking for clarity in the haze of the pandemic.

Butardo, et al, COVID and Brain Fog

- IADECOLA, C., ANRATHER, J., & KAMEL, H. (2020). Effects of COVID-19 on the
- 673 nervous system. *Cell*, *183*(1), 16-27. e11.
- JULAYANONT, P., & NASREDDINE, Z. S. (2017). Montreal Cognitive Assessment
- 675 (MoCA): concept and clinical review. In *Cognitive screening instruments* (pp.
- 676 139-195). Springer.
- 677 KUMARI, P., ROTHAN, H. A., NATEKAR, J. P., STONE, S., PATHAK, H., STRATE,
- 678 P. G., ARORA, K., BRINTON, M. A., & KUMAR, M. (2021). Neuroinvasion
- and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-
- 680 hACE2 mice. *Viruses*, *13*(1), 132.
- LECHIEN, J. R., CHIESA-ESTOMBA, C. M., DE SIATI, D. R., HOROI, M., LE BON,
- 682 S. D., RODRIGUEZ, A., DEQUANTER, D., BLECIC, S., EL AFIA, F., &
- 683 DISTINGUIN, L. (2020). Olfactory and gustatory dysfunctions as a clinical
- 684 presentation of mild-to-moderate forms of the coronavirus disease (COVID-
- 685 19): a multicenter European study. *European Archives of Oto-rhino-*
- 686 *laryngology*, 277(8), 2251-2261.
- 687 LOCKWOOD, C., MUNN, Z., & PORRITT, K. (2015). Qualitative research synthesis:
- 688 methodological guidance for systematic reviewers utilizing meta-aggregation.
- *JBI Evidence Implementation*, *13*(3), 179-187.
- 690 MIELKE, M. M., PRZYBELSKI, S. A., LESNICK, T. G., KERN, S., ZETTERBERG,
- 691 H., BLENNOW, K., KNOPMAN, D. S., GRAFF-RADFORD, J., PETERSEN, R.
- 692 C., & JACK JR, C. R. (2021). Comparison of CSF neurofilament light chain,
- 693 neurogranin, and tau to MRI markers. *Alzheimer's & Dementia*, 17(5), 801-
- 694 **812**.
- 695 MISKOWIAK, K., JOHNSEN, S., SATTLER, S., NIELSEN, S., KUNALAN, K.,
- 696 RUNGBY, J., LAPPERRE, T., & PORSBERG, C. (2021). Cognitive

impairments four months after COVID-19 hospital discharge: pattern, severity

Butardo, et al, COVID and Brain Fog

697

29

698	and association with illness variables. European Neuropsychopharmacology,
699	46, 39-48.
700	MUNN, Z., STERN, C., AROMATARIS, E., LOCKWOOD, C., & JORDAN, Z. (2018).
701	What kind of systematic review should I conduct? A proposed typology and
702	guidance for systematic reviewers in the medical and health sciences. BMC
703	medical research methodology, 18(1), 1-9.
704	NALBANDIAN, A., SEHGAL, K., GUPTA, A., MADHAVAN, M. V., MCGRODER, C.,
705	STEVENS, J. S., COOK, J. R., NORDVIG, A. S., SHALEV, D., &
706	SEHRAWAT, T. S. (2021). Post-acute COVID-19 syndrome. Nature medicine,
707	27(4), 601-615.
708	NEGRINI, F., FERRARIO, I., MAZZIOTTI, D., BERCHICCI, M., BONAZZI, M., DE
709	SIRE, A., NEGRINI, S., & ZAPPAROLI, L. (2021). Neuropsychological
710	features of severe hospitalized coronavirus disease 2019 patients at clinical
711	stability and clues for postacute rehabilitation. Archives of Physical Medicine
712	and Rehabilitation, 102(1), 155-158.
713	ORTELLI, P., FERRAZZOLI, D., SEBASTIANELLI, L., ENGL, M., ROMANELLO, R.,
714	NARDONE, R., BONINI, I., KOCH, G., SALTUARI, L., & QUARTARONE, A.
745	(0004) Neuropeus hale signal and a summa husis la signal semalata a stifation a in

- 715 (2021). Neuropsychological and neurophysiological correlates of fatigue in
- 716 post-acute patients with neurological manifestations of COVID-19: Insights
- into a challenging symptom. *Journal of the neurological sciences*, 420,

718 117271.

- 719 POPAY, J., ROBERTS, H., SOWDEN, A., PETTICREW, M., ARAI, L., RODGERS,
- 720 M., BRITTEN, N., ROEN, K., & DUFFY, S. (2006). Guidance on the conduct

30

	Butardo, <i>et al,</i> COVID and Brain Fog 30
721	of narrative synthesis in systematic reviews. A product from the ESRC
722	methods programme Version, 1, b92.
723	PUCHNER, B., SAHANIC, S., KIRCHMAIR, R., PIZZINI, A., SONNWEBER, B.,
724	WÖLL, E., MÜHLBACHER, A., GARIMORTH, K., DAREB, B., & EHLING, R.
725	(2021). Beneficial effects of multi-disciplinary rehabilitation in postacute
726	COVID-19: an observational cohort study. Eur J Phys Rehabil Med, 189-198.
727	SALCAN, İ., KARAKEÇILI, F., SALCAN, S., ÜNVER, E., AKYÜZ, S., SEÇKIN, E., &
728	CINGI, C. (2021). Is taste and smell impairment irreversible in COVID-19
729	patients? European Archives of Oto-rhino-laryngology, 278(2), 411-415.
730	TAY, M. R. J., LOW, Y. H., LIM, C. C. T., UMAPATHI, T., THIO, J. M. L., LUI, W. L.,
731	CHAN, W. L. W., & CHUA, K. S. G. (2021). Covert subclinical neurocognitive
732	sequelae during the rehabilitation course of severe Coronavirus Disease
733	2019. American journal of physical medicine & rehabilitation, 100(1), 39-43.
734	TENFORDE, M. W., KIM, S. S., LINDSELL, C. J., ROSE, E. B., SHAPIRO, N. I.,
735	FILES, D. C., GIBBS, K. W., ERICKSON, H. L., STEINGRUB, J. S., &
736	SMITHLINE, H. A. (2020). Symptom duration and risk factors for delayed
737	return to usual health among outpatients with COVID-19 in a multistate health
738	care systems network—United States, March–June 2020. Morbidity and
739	Mortality Weekly Report, 69(30), 993.
740	VANDENBROUCKE, J. P., VON ELM, E., ALTMAN, D. G., GØTZSCHE, P. C.,

MULROW, C. D., POCOCK, S. J., POOLE, C., SCHLESSELMAN, J. J., 741

- EGGER, M., & INITIATIVE, S. (2007). Strengthening the Reporting of 742
- Observational Studies in Epidemiology (STROBE): explanation and 743
- elaboration. PLoS medicine, 4(10), e297. 744

Butardo, et al, COVID and Brain Fog

745	VANNORSDALL, T. D., BRIGHAM, E., FAWZY, A., RAJU, S., GORGONE, A.,
746	PLETNIKOVA, A., LYKETSOS, C. G., PARKER, A. M., & OH, E. S. (2022).
747	Cognitive Dysfunction, Psychiatric Distress, and Functional Decline After
748	COVID-19. Journal of the Academy of Consultation-liaison Psychiatry, 63(2),
749	133-143.
750	VINKERS, C. H., VAN AMELSVOORT, T., BISSON, J. I., BRANCHI, I., CRYAN, J.
751	F., DOMSCHKE, K., HOWES, O. D., MANCHIA, M., PINTO, L., & DE
752	QUERVAIN, D. (2020). Stress resilience during the coronavirus pandemic.
753	European Neuropsychopharmacology, 35, 12-16.
754	VIRHAMMAR, J., NÄÄS, A., FÄLLMAR, D., CUNNINGHAM, J. L., KLANG, A.,
755	ASHTON, N. J., JACKMANN, S., WESTMAN, G., FRITHIOF, R., &
756	BLENNOW, K. (2021). Biomarkers for central nervous system injury in
757	cerebrospinal fluid are elevated in COVID-19 and associated with neurological
758	symptoms and disease severity. European journal of neurology, 28(10), 3324-
759	3331.
760	WHITTAKER, A., ANSON, M., & HARKY, A. (2020). Neurological manifestations of
761	COVID-19: a systematic review and current update. Acta Neurologica
762	Scandinavica, 142(1), 14-22.
763	WILD, C., NORTON, L., MENON, D., RIPSMAN, D., SWARTZ, R., & OWEN, A.
764	(2021). Seeing through brain fog: disentangling the cognitive, physical, and
765	mental health sequalae of COVID-19.
766	WOO, M. S., MALSY, J., PÖTTGEN, J., SEDDIQ ZAI, S., UFER, F., HADJILAOU,
767	A., SCHMIEDEL, S., ADDO, M. M., GERLOFF, C., & HEESEN, C. (2020).
768	Frequent neurocognitive deficits after recovery from mild COVID-19. Brain
769	communications, 2(2), fcaa205.

Butardo, et al, COVID and Brain Fog

770	YESILKAYA, U. H., SEN, M., & BALCIOGLU, Y. H. (2021). COVID-19-related
771	cognitive dysfunction may be associated with transient disruption in the
772	DLPFC glutamatergic pathway. Journal of Clinical Neuroscience, 87, 153-155.
773	
774	ZHOU, H., LU, S., CHEN, J., WEI, N., WANG, D., LYU, H., SHI, C., & HU, S. (2020).
775	The landscape of cognitive function in recovered COVID-19 patients. Journal
776	of psychiatric research, 129, 98-102.
777	ZOU, L., RUAN, F., HUANG, M., LIANG, L., HUANG, H., HONG, Z., YU, J., KANG,
778	M., SONG, Y., & XIA, J. (2020). SARS-CoV-2 viral load in upper respiratory
779	specimens of infected patients. New England Journal of Medicine, 382(12),
780	1177-1179.
781	
782	
783	
784	
785	
786	
787	
788	
789	
790	
791	
792	
793	
794	

Butardo, et al, COVID and Brain Fog

33

# 795

# **Tables and Figures**

796

797 **Table 1.** Characteristics of included studies (n=13).

Author (Year)	Sample Size	Population Mean Age/ Median Age* (Range)	Study Design	Outcome/s
Beach et al. (2020)	4	75.25 yo (68- 87)	Case series	Neuropsychological and neurophysiological features of fatigue were studied in post-COVID-19 patients. In addition, apathy, deficits in executive functions, and reduction in global cognition were found.
Blazhenets et al. (2021)	31	66.00 yo (39- 89)	Cohort	MOCA <i>M</i> = 19.13; 23.38 Impaired language, visuospatial function, memory, and executive function
Garcia, M.A. et al. (2021)	18	56 yo*(20-79 yo; 14 healthy, 68 non-COVID- 19 neurological disease controls)	Cross- sectional	Neuroinflammatory processes in COVID-19 CSF may be the result of a homeostatic neurological response rather than an adaptive, immune- mediated cytokine storm or inflammation caused by neurovirulence. Mild, moderate, severe, and critical cases exhibited cognitive deficits, regardless of severity.
Garcia, M.H.C. et al. (2021)	199	43 yo (>18 yo)	Cross- sectional	Mild to moderate cases of COVID-19 severity exhibited cognitive deficits
Graham et al. (2021)	-		Cohort	Patients and controls had mild to moderate cognitive dysfunction but showed no significant difference
Hosp et al. (2021)	29	65.2 yo (>18)	Cohort	MOCA <i>M</i> = 21.77 Impaired attention, visuospatial function, memory, and executive function
Ortelli et al. (2020)	12	67 yo (48-80)	Cross- sectional	MOCA $M$ = 17.80 Impaired attention via SIT and NT but unimpaired attention on VT

Butardo, et al, COVID and Brain Fog

Author (Year)	Sample Size	Population Mean Age/ Median Age* (Range)	Study Design	Outcome/s
Puchner et al. (2021)	23	57 yo (≥18)	Cohort	In 29% of tested patients, cognitive deficits in concentration, memory, and/or executive functions were found.
Vannorsdall et al. (2022)	82	54.5 yo (>16)	Cohort	Impaired scores for Oral Trail Making Test, Verbal Fluency, and Rey Auditory Verbal Learning Test Critically ill patients exhibited cognitive deficits.
Virhammar et al. (2021)	19	64 yo (34-76)	Cohort	Majority of patients presented with increased CSF levels of neuronal injury markers. Results of the study show that there is no specific pattern in the manifestation of brain fog across illness severity.
Woo et al. (2020)	18	42.11 yo (17- 71)	Cross- sectional	TICS-M: COVID-19 patients scored significantly lower than HC, especially in memory, attention, and language. Patients with mild to moderate case severity indicated manifestation of cognitive dysfunction.
Yesilkaya et al. (2021)	1	20 уо	Case report	Cognitive deficits in SARS-CoV-2 infection can result from glutamatergic dysfunction with decreased glutamate and NAA levels in the DLPFC confirmed by MRS.
Zhou et al. (2020)	29	47 yo (30-64)	Cross- sectional	CPT: COVID-19 patients performed significantly worse than HC No significance for TMT, SCT, and DST between the two groups

Butardo, et al, COVID and Brain Fog

35

# 803 Table 2. Summary of domain-specific and non-domain-specific test results of included

804 studies (n=7).

				Cognitive Domains*						
Author	Sample Size	Sample MoCA global Size score (> 26)		0	A	L	VSF	Μ	EF	
Blazhenets et al. (2021)	8	1st exam		x	х	~	√	$\checkmark$	$\checkmark$	
		19.13	23.38							
Graham et al. (2021)	50	n/a		n/a	$\checkmark$	n/a	n/a	$\checkmark$	$\checkmark$	
Hosp et al. (2021)	26	21.77		x	$\checkmark$	x	$\checkmark$	$\checkmark$	$\checkmark$	
Ortelli et al. (2020)	12	17.80		n/a	$\checkmark$	n/a	n/a	n/a	$\checkmark$	
Vannorsdall et al. (2021)	82	n/a		n/a	х	$\checkmark$	n/a	$\checkmark$	$\checkmark$	
Woo et al. (2020)	18	n/a		$\checkmark$	$\checkmark$	$\checkmark$	n/a	$\checkmark$	n/a	
Zhou et al. (2020)	29	n/a		n/a	$\checkmark$	n/a	x	х	x	

805

806

807 Legend: O – Orientation; A – Attention; L – Language, VSF – Visuospatial Function;

\* $\checkmark$ : impaired domain; X: unimpaired domain; n/a: no available data.

808 M – Memory; EF – Executive Function

809


Butardo, et al, COVID and Brain Fog

# **Table 3.** Summary of occurrence of cognitive dysfunction across illness severity from

# 812 included studies (n=5).

Author	Clinical Spe	Cognitive				
(Year)	Asymptomatic or Presymptomatic Infection	Mild Illness	Moderate Illness	Severe Illness	Critical Illness	dysfunction
Garcia MA et al. (2021)	Х	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$
Garcia MHC et al. (2021)	Х	$\checkmark$	$\checkmark$	Х	Х	$\checkmark$
Vannorsdall et al. (2022)	Х	Х	Х	Х	$\checkmark$	$\checkmark$
Virhammar et al. (2021)	Х	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$
Woo et al. (2020)	Х	$\checkmark$	$\checkmark$	Х	Х	$\checkmark$

#### Butardo, et al, COVID and Brain Fog






Figure 1. PRISMA flow diagram.